论文部分内容阅读
目的探析卡托普利联合丹参酮治疗急性发作期肺源性心脏病(肺心病)的疗效。方法 80例急性发作期肺心病患者,随机分为观察组与对照组,各40例。两组患者均给予常规对症疗法,对照组患者给予卡托普利治疗,观察组患者在对照组基础上加用丹参酮治疗,对比两组治疗效果及不良反应情况。结果经治疗,观察组患者总有效率为97.5%,明显高于对照组的82.5%,差异具有统计学意义(χ~2=5.000,P<0.05)。观察组患者不良反应发生率为7.5%,与对照组的2.5%比较,差异无统计学意义(χ~2=1.053,P>0.05)。两组患者的不良反应均较为轻微,未经处理即缓解。结论卡托普利联合丹参酮治疗急性发作期肺心病疗效确切,用药安全性高,值得推广。
Objective To investigate the curative effect of captopril and tanshinone in the treatment of acute pulmonary heart disease (pulmonary heart disease). Methods Eighty patients with acute episode of pulmonary heart disease were randomly divided into observation group and control group, 40 cases in each. Both groups were given conventional symptomatic therapy, patients in the control group were treated with captopril, and the patients in the observation group were treated with tanshinone on the basis of the control group. The therapeutic effects and adverse reactions were compared between the two groups. Results After treatment, the total effective rate in the observation group was 97.5%, which was significantly higher than that in the control group (82.5%). The difference was statistically significant (χ ~ 2 = 5.000, P <0.05). The incidence of adverse reactions in the observation group was 7.5%, which was not significantly different from that in the control group (χ ~ 2 = 1.053, P> 0.05). Adverse reactions were mild in both groups and were relieved without treatment. Conclusion Captopril combined with tanshinone in the treatment of acute episode of pulmonary heart disease is effective and safe. It is worth promoting.